Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00600600 · ClinicalTrials.gov registry record · Phase 2
Tigecycline for Treatment of Rapidly Growing Mycobacteria
A Phase 2 study, sponsored by The University of Texas Health Science Center at Tyler.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT00600600: Completed Phase 2 study, sponsored by The University of Texas Health Science Center at Tyler.
NCT00600600 is a Phase 2 study that has completed, run by The University of Texas Health Science Center at Tyler. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00600600, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center at Tyler.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
To determine the safety, tolerance, and efficacy of Tigecycline when given daily to patients with rapidly growing mycobacterial disease (especially M.abscessus).
Interventions
- DRUG Tigecycline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2002-04 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00600600
The ClinicalTrials.gov registry entry for NCT00600600 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). The listed sponsor is The University of Texas Health Science Center at Tyler, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tigecycline is the first listed.
NCT00600600 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00600600 about?
NCT00600600 is a clinical study titled "Tigecycline for Treatment of Rapidly Growing Mycobacteria". To determine the safety, tolerance, and efficacy of Tigecycline when given daily to patients with rapidly growing mycobacterial disease (especially M.abscessus).
What is the current status of trial NCT00600600?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2002-04. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00600600?
The interventions under investigation include: Tigecycline (DRUG).
Who is sponsoring clinical trial NCT00600600?
This trial is sponsored by The University of Texas Health Science Center at Tyler, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.